Sonoma Pharmaceuticals Overview

  • Founded
  • 1999

Founded
  • Status
  • Public

  • Employees
  • 177

Employees
  • Stock Symbol
  • SNOA

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $3.01

  • (As of Wednesday Closing)

Sonoma Pharmaceuticals General Information

Description

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.

Contact Information

Formerly Known As
Micromed Laboratories, Oculus Innovative Sciences
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Stock Exchange
NAS
Primary Office
  • 1129 North McDowell Boulevard
  • Petaluma, CA 94954
  • United States
+1 (707) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sonoma Pharmaceuticals Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.01 $3.10 $2.55 - $13.36 $9.6M 3.1M 79.1K -$1.71

Sonoma Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 1,850 5,103 11,875 6,081
Revenue 12,927 12,628 18,629 17,928
EBITDA (5,064) (5,222) (3,679) (3,266)
Net Income (4,875) (5,086) (3,950) (3,308)
Total Assets 17,158 18,845 14,987 14,561
Total Debt 952 1,367 2,675 850
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sonoma Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sonoma Pharmaceuticals‘s full profile, request access.

Request a free trial

Sonoma Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identi
Surgical Devices
Petaluma, CA
177 As of 2022
00000
00000000 00000

000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
00000000 0000000
Lewisville, TX
0000 As of 0000
00000000

0000 0

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
00000000 0000000
Malvern, PA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sonoma Pharmaceuticals Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orthofix International Formerly PE-Backed Lewisville, TX 0000 00000000
0000 000 Formerly VC-backed Malvern, PA 000 00000 00000000 00000
000000 Corporation Marietta, GA 000 00000 000000000 00000
00000 Formerly VC-backed Columbia, MD 000 000.00 000000&0 000.00
000000 000000 Corporation Warsaw, IN 00000 00.000 000000 - 000 00.000
To view Sonoma Pharmaceuticals’s complete competitors history, request access »

Sonoma Pharmaceuticals Patents

Sonoma Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9918477-B2 Stabilized hypochlorous acid solution and use thereof Active 22-May-2013 000000000
US-20160120183-A1 Stabilized hypochlorous acid solution and use thereof Granted 22-May-2013 000000000
US-10412969-B2 Stabilized hypochlorous acid solution and use thereof Active 22-May-2013 000000000
US-20180206502-A1 Stabilized hypochlorous acid solution and use thereof Granted 22-May-2013 000000000
JP-2016521684-A Stabilized hypochlorous acid solution and use thereof Granted 22-May-2013 A01N59/00
To view Sonoma Pharmaceuticals’s complete patent history, request access »

Sonoma Pharmaceuticals Executive Team (15)

Name Title Board Seat Contact Info
Amy Trombly Chief Executive Officer & Board Member
Jerome Dvonch Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Bruce Thornton Chief Operating Officer, Operations & Secretary, Administration
James Allison Director, Finance & Compliance
Robert Northey Ph.D Executive Vice President
You’re viewing 5 of 15 executive team members. Get the full list »

Sonoma Pharmaceuticals Board Members (12)

Name Representing Role Since
Amy Trombly Sonoma Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Jay Birnbaum Ph.D Self Board Member 000 0000
Jerry McLaughlin Self Board Member 000 0000
Philippe Weigerstorfer Sonoma Pharmaceuticals Board Member 000 0000
You’re viewing 4 of 12 board members. Get the full list »

Sonoma Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sonoma Pharmaceuticals Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0.0. 00000000 01-Jan-2015 000000000 Buildings and Property
To view Sonoma Pharmaceuticals’s complete investments history, request access »